AGILeBiotics further develops novel antibiotics

Tuesday 7 August 2018

  • Life Cooperative

AGILe Biotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant bacteria. On the 18th of July 2018, AGILe Biotics came to an agreement for joint investment from in total five regional investors. Carduso Capital and Pharma Connect Capital became new shareholders with the recently acquired investment. 

With this financial support, AGILe Biotics is further developing novel antibiotics enriching its proprietary drug pipeline. With having now also Pharma Connect Capital and Carduso Capital on board, the spin-off company aims to enter clinical studies in 2020. 

One year work in two days

The antibiotic resistance increases and the treatment options decrease. The most successful strategy for introducing new antibiotics (chemical synthesis) takes a lot of time, in the range of years. This is where AGILeBiotics comes in, of course in close contact with researchers from the Centre for Sustainable Antimicrobials (CeSAM) - a collaboration of several University of Groningen research institutes and the University Medical Center Groningen, focused on tackling antimicrobial resistance - and with local life science SMEs. The patented technology platform of AGILeBiotics brings back one-year's work of synthesis to just two days. You can imagine what this does with the chance of finding new antibiotics, and thus finding new treatment options.

About AGILe Biotics

AGILe Biotics BV was launched in March 2017 as a spin-off company from the University of Groningen (UG). With a pre-seed investment received from Hanzepoort BV, RUG Houdstermaatschappij BV and Stichting ir. G.J. Smid Fonds BV in 2017, AGILe Biotics has already identified promising lead compounds showing superior activity against clinical bacterial isolates. Compared to current treatment options, those antibiotic candidates show improved activity against resistant pathogens and broader activity not only against Gram-negative, but also Gram-positive bacteria. 

AGILeBiotics highlighted
AGILeBiotics highlighted

Focus areas

Life Cooperative